CN

Adhere to quality control, create superior products

R&D center

3SBio always regards product quality as the lifeline of the enterprise.

The Group has the National Engineering Research Center of Antibody Medicine approved by the National Development and Reform Commission. Members of its Academic Committee are all composed of authoritative academicians and well-known experts. We established 4 major R&D bases in Shenyang, Shanghai, Shenzhen and Hangzhou, successfully building the dual platform for biological and chemical drug, covering the whole process of drug development, ranging from basic research, pre-clinical study, and clinical trial to new drug registration and marketing.

R&D platform

We have three R&D platforms, including two protein-based biopharmaceutical platforms (a cellular platform for mammalian expression system and a platform for bacterial cell expression system) and a chemical platform.

R&D process

Our findings and pre-clinical studies involve the following general steps:

We continue to research process development and control throughout the pre-clinical and clinical stages until the commercialization of the product. The R&D project is carried out by four departments within the company: